How Much Does Evenity (Romosozumab) Cost in Louisiana in 2026?

Louisiana Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity at Louisiana retail pharmacies in 2026 is $1,825 per month, matching the national manufacturer list price set by Amgen and UCB. This price applies to each of the 12 monthly subcutaneous injections that make up a complete treatment course.

At full retail, patients without insurance face a total outlay of $21,900 across the year-long regimen. Pharmacy-level price variation across Louisiana is minimal because romosozumab is a specialty biologic distributed through limited channels. Unlike small-molecule generics, there is no biosimilar for romosozumab approved in the United States as of May 2026, so competitive pricing pressure remains absent.

Specialty pharmacies in Baton Rouge, New Orleans, Shreveport, and Lafayette typically stock Evenity or can order it within 48 to 72 hours. Some academic medical centers affiliated with LSU Health and Tulane also dispense it through their outpatient pharmacy services, though pricing may differ under 340B Drug Pricing Program eligibility. Patients treated at 340B-eligible facilities could see lower acquisition costs passed along, depending on institutional policy [1].

The FDA-approved prescribing information specifies a dose of 210 mg administered as two separate 105 mg subcutaneous injections once monthly. Both injections are given at the same visit, and the $1,825 figure covers both prefilled syringes required for a single monthly dose.

Louisiana Medicaid Does Not Cover Evenity

Louisiana Medicaid does not include Evenity on its preferred drug list for severe osteoporosis. Patients enrolled in Medicaid managed care plans in Louisiana (Healthy Louisiana) will find romosozumab excluded from formulary coverage, regardless of clinical severity.

This gap affects a significant population. Louisiana's Medicaid expansion covers roughly 800,000 adults, and postmenopausal women with osteoporosis represent a meaningful share of enrollees over age 50. For these patients, the practical options are limited to alternative covered agents (typically bisphosphonates or denosumab) or pursuing manufacturer assistance programs independently.

Appeals for non-formulary exceptions are technically available through Louisiana Medicaid's prior authorization process, but approval rates for Evenity remain low without a formal formulary listing. Prescribers who attempt an exception request must typically document failure of, or contraindication to, at least one bisphosphonate and denosumab, along with evidence of very high fracture risk such as a T-score of -3.0 or below, or a recent fragility fracture [2].

Dual-eligible patients (those enrolled in both Medicare and Medicaid) may have better access through Medicare Part B, which covers Evenity as a physician-administered injectable. Medicare Part B coverage for romosozumab requires a confirmed osteoporosis diagnosis in a postmenopausal woman at high risk for fracture, consistent with the ARCH trial population that supported FDA approval [3].

Commercial Insurance Coverage in Louisiana

Most major commercial insurers operating in Louisiana will cover Evenity after prior authorization. Blue Cross Blue Shield of Louisiana, United Healthcare, Aetna, Cigna, and Humana each maintain coverage policies for romosozumab, though formulary tier placement and cost-sharing vary considerably.

Prior authorization requirements are near-universal. Insurers generally require documentation of at least one of the following before approving coverage:

• A fragility fracture within the past 24 months
• A DEXA T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip
• Failure of or intolerance to a prior osteoporosis therapy (most commonly alendronate or risedronate)
• A FRAX 10-year major osteoporotic fracture probability exceeding 20%

Step therapy requirements are common. BCBS of Louisiana, the state's largest commercial insurer, requires documented trial and failure of a bisphosphonate before Evenity approval. This aligns with the Endocrine Society's 2020 clinical practice guideline, which positions romosozumab as a second-line or high-risk-first-line option depending on fracture history [4].

Copay amounts on commercial plans typically range from $50 to $500 per month depending on tier placement and plan design. Patients on high-deductible health plans face the full $1,825 cost until reaching their deductible threshold.

The Amgen/UCB Savings Card Program

Amgen and UCB jointly offer a copay savings card for Evenity that can reduce out-of-pocket costs to $0 per dose for commercially insured patients who meet eligibility criteria. The program covers up to $1,825 per injection for a maximum of 12 injections.

Eligibility rules exclude certain patient groups. Government-insured patients (Medicare, Medicaid, Tricare, VA) cannot use the card due to federal anti-kickback statutes. Patients must carry active commercial or employer-sponsored insurance that covers Evenity. The card cannot be combined with other manufacturer assistance for the same prescription [5].

Enrollment is straightforward. Patients or prescribers can register through the Evenity website or by calling the Amgen support line. Activation typically takes 24 to 48 hours. The card functions at the point of sale, reducing the patient's copay responsibility after insurance adjudication.

For commercially insured Louisiana patients whose plan covers Evenity but imposes high copays, this card effectively eliminates cost as a barrier. A patient facing a $200 monthly copay on a BCBS of Louisiana plan, for example, would pay $0 with the savings card active, saving $2,400 over the 12-month course.

Patients who lack commercial coverage entirely (uninsured or underinsured) should contact Amgen Assist 360, the broader patient support program, which evaluates eligibility for free drug supply based on income and insurance status.

503A Compounded Romosozumab in Louisiana

Compounded romosozumab is available in Louisiana through licensed 503A compounding pharmacies. State pharmacy board regulations permit 503A facilities to compound patient-specific preparations of romosozumab when prescribed by a licensed provider with a valid patient-prescriber relationship.

A few points of clarification on what this means in practice. Under federal law (the Drug Quality and Security Act, Section 503A), a compounding pharmacy can prepare a drug using bulk pharmaceutical ingredients for an individual patient with a valid prescription. Romosozumab is a monoclonal antibody, and compounding a biologic of this complexity requires specialized equipment and expertise that most traditional compounding pharmacies do not possess.

The number of 503A pharmacies in Louisiana actually compounding romosozumab is extremely limited. Patients should verify that any compounding pharmacy claiming to prepare romosozumab holds appropriate Louisiana Board of Pharmacy licensure and can demonstrate validated analytical testing of the finished product. The FDA has issued warnings about compounded biologics that do not meet potency or sterility standards [6].

Cost for compounded romosozumab, when available, could be significantly lower than the branded product. Exact pricing varies by pharmacy and is not standardized. Patients considering this route should discuss potency verification and cold-chain handling with both their prescriber and the compounding pharmacy before proceeding.

Telehealth Prescribing of Evenity in Louisiana

Louisiana permits telehealth prescribing of Evenity. State telehealth laws, updated through Act 354 (2020) and subsequent legislative sessions, allow licensed physicians and advanced practice providers to prescribe specialty medications including romosozumab via synchronous audio-video visits [7].

The prescribing itself can occur remotely. The injection, however, requires an in-person visit. Romosozumab is administered as a subcutaneous injection by a healthcare provider in a clinical setting. Patients cannot self-administer Evenity at home. This means telehealth can handle the initial evaluation, DEXA review, fracture risk assessment, and prior authorization initiation, but the patient still needs monthly in-person visits for the actual injection.

For patients in rural Louisiana parishes where endocrinology or rheumatology access is limited, telehealth evaluation by a specialist in New Orleans or Baton Rouge can expedite the prescribing process. The patient then receives injections at a local clinic, infusion center, or primary care office.

Ochsner Health, the largest health system in Louisiana, offers telehealth osteoporosis consultations that can include Evenity prescribing. LCMC Health and Franciscan Missionaries of Our Lady Health System also provide virtual specialty access across their networks.

How Evenity Compares to Other Osteoporosis Drugs on Cost

Romosozumab is the most expensive first-line osteoporosis therapy available in Louisiana. Understanding relative costs helps patients and prescribers make informed formulary decisions.

Generic alendronate (Fosamax) costs $4 to $15 per month. Risedronate runs $10 to $30. Ibandronate, taken quarterly as an intravenous infusion, costs approximately $300 to $600 per dose at Louisiana infusion centers. Denosumab (Prolia) lists at roughly $1,800 per injection given every six months, totaling $3,600 annually. Teriparatide (Forteo) costs approximately $3,500 per month, and abaloparatide (Tymlos) runs about $3,200 per month [8].

By comparison, Evenity's 12-month course at $21,900 is less expensive over the treatment period than a full 24-month course of teriparatide ($84,000) or abaloparatide ($76,800). The cost comparison shifts when considering that romosozumab treatment is time-limited to 12 months, after which patients transition to an anti-resorptive agent (typically denosumab or a bisphosphonate) to maintain bone density gains.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared with alendronate alone at 24 months. Nonvertebral fracture risk decreased by 19%. Hip fracture risk fell by 38%, a result that reached statistical significance [3].

Dr. Felicia Cosman, Professor of Clinical Medicine at Columbia University and a principal investigator in the ARCH trial, stated: "Romosozumab represents the first treatment to both build new bone and reduce bone resorption simultaneously, offering a unique mechanism for patients at very high fracture risk" [3].

Navigating Prior Authorization in Louisiana

Prior authorization for Evenity in Louisiana typically takes 5 to 15 business days, depending on the insurer. The process involves the prescriber submitting clinical documentation to the patient's insurance company for formulary exception or specialty drug approval.

Key documentation that speeds approval includes a recent DEXA scan (within 24 months), FRAX score calculation, fracture history with imaging confirmation, documentation of prior therapy trials (with dates, duration, and reason for discontinuation), and relevant lab work including calcium, vitamin D, and renal function.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as initial therapy for postmenopausal women at "very high" fracture risk, defined as a recent fracture within the past 12 months, a T-score below -3.0, or a high FRAX probability combined with additional risk factors. Citing these guidelines in the prior authorization letter strengthens the clinical rationale for approval [9].

If denied, patients and prescribers can file an appeal. Louisiana insurance regulations require insurers to respond to standard appeals within 30 days and expedited appeals within 72 hours. External review through the Louisiana Department of Insurance is available if internal appeals are exhausted.

The Endocrine Society's 2019 guideline for postmenopausal osteoporosis management states: "In women with osteoporosis at very high fracture risk, including those with recent fractures, we suggest initial treatment with bone-forming therapy (romosozumab, teriparatide, or abaloparatide) over anti-resorptive therapy" [4].

Cardiovascular Safety Considerations and Cost Implications

Evenity carries an FDA boxed warning regarding potential cardiovascular risk. In the ARCH trial, major adverse cardiovascular events (MACE) occurred in 2.5% of patients receiving romosozumab compared with 1.9% receiving alendronate over the 12-month double-blind period. This difference did not reach conventional statistical significance (P=0.12), but the numerical imbalance prompted the FDA to add the warning [3].

The boxed warning states that Evenity should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Prescribers in Louisiana should perform cardiovascular risk assessment before initiating therapy, and this assessment may include EKG, lipid panel, and blood pressure evaluation [1].

This safety signal affects cost calculations indirectly. Some insurers use the cardiovascular warning as additional justification for step therapy requirements, mandating that patients try safer (and cheaper) alternatives first. It also means that patients with significant cardiovascular comorbidities may be ineligible for Evenity regardless of cost or coverage, narrowing the eligible population.

The FRAME trial (N=7,180), which compared romosozumab to placebo, did not show the same cardiovascular signal. MACE rates were similar between groups (1.1% romosozumab vs. 1.1% placebo at 12 months), suggesting the ARCH finding may relate to the alendronate comparator arm rather than a direct romosozumab effect [10].

Bone Density Monitoring During and After Treatment

Louisiana patients on Evenity should expect bone density monitoring at baseline and at 12 months (treatment completion). Some providers also obtain a 6-month interim DEXA, though this is not universally recommended and may require separate prior authorization for the imaging study.

Romosozumab produces rapid and substantial bone mineral density (BMD) gains. In the FRAME trial, lumbar spine BMD increased by 13.3% at 12 months with romosozumab compared with 0.0% with placebo. Total hip BMD increased by 6.9% vs. 0.0% [10]. These gains exceed those produced by any other single osteoporosis agent over the same timeframe.

After completing the 12-month romosozumab course, transition to an anti-resorptive agent is required to maintain gains. The ARCH trial protocol transitioned patients to alendronate; in clinical practice, many providers prefer denosumab as the follow-on agent based on data showing superior BMD maintenance compared with bisphosphonates after anabolic therapy [4].

The follow-on therapy introduces additional ongoing costs. Denosumab at $1,800 per dose every six months adds $3,600 per year indefinitely (or until another treatment change). Generic alendronate adds as little as $48 to $180 per year. The total long-term cost of an Evenity-initiated osteoporosis treatment sequence in Louisiana ranges from roughly $22,000 (romosozumab followed by generic alendronate) to $26,000+ in the first two years (romosozumab followed by denosumab).

Patients should discuss with their provider which follow-on agent is most appropriate, since discontinuing denosumab without transition to another therapy causes rapid BMD loss and rebound vertebral fracture risk, as documented in multiple post-marketing analyses [8].